Open label trial of anakinra in active ankylosing spondylitis over 24 weeks

Annals of the Rheumatic Diseases

Volumn 64, Issue 2, 2005, Pages 296-298

  Haibel, H ^a   Rudwaleit, M ^a   Listing, J ^b   Sieper, J ^a,b  

^a CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^b German Natl Research Cent for   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

C REACTIVE PROTEIN; GADOLINIUM PENTETATE; INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; NONSTEROID ANTIINFLAMMATORY AGENT; RECOMBINANT INTERLEUKIN 1 RECEPTOR BLOCKING AGENT;

ADULT; ANKYLOSING SPONDYLITIS; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE ACTIVITY; DRUG TOLERABILITY; FEMALE; FUNCTIONAL ASSESSMENT; HUMAN; INFECTION; INJECTION SITE REACTION; JOINT FUNCTION; MALE; NUCLEAR MAGNETIC RESONANCE IMAGING; OPPORTUNISTIC INFECTION; PAIN ASSESSMENT; PHYSICAL EXAMINATION; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; QUALITY OF LIFE; SACROILIAC JOINT; SIDE EFFECT; TREATMENT OUTCOME; WILCOXON SIGNED RANKS TEST;

ADULT; ANTIRHEUMATIC AGENTS; FEMALE; FOLLOW-UP STUDIES; HEALTH STATUS INDICATORS; HUMANS; INTERLEUKIN 1 RECEPTOR ANTAGONIST PROTEIN; MAGNETIC RESONANCE IMAGING; MALE; MIDDLE AGED; RECEPTORS, INTERLEUKIN-1; RECOMBINANT PROTEINS; SIALOGLYCOPROTEINS; SPONDYLITIS, ANKYLOSING; TREATMENT OUTCOME;

EID: 13244279795     PISSN: 00034967     EISSN: None     Source Type: Journal    
DOI: 10.1136/ard.2004.023176     Document Type: Article

References (15)

1. Braun J, Bollow M, Remlinger G, Eggens U, Rudwaleit M, Distler A, et al. Prevalence of spondyloarthritides in HLA B27-positive and -negative bload donors. Arthritis Rheum 1998;41:58-67.
2. Dougados M, van der Linden S, Leirisalo-Repo M, Huitfeldt B, Juhlin R, Veys E, et al. Sulfasalazine in the treatment of spondyloarthritides. Arthritis Rheum 1995;38:618-27.
3. Braun J, Brandt J, Listing J, Zink A, Alten R, Krause A, et al. Treatment of active onkylosing spondylitis with inftiximab - a double-blind placebo controlled multicenter trial. Lancet 2002;359:1187-93.
4. Brandt J, Khariouzov A, Listing J, Haibel H, Sorensen H, Grassnickel L, et al. Six months results of a double-blind placebo controlled clinical trial of etanercept in active ankylosing spondylitis. Arthritis Rheum 2003;48:1667-75.
5. Davis JC, Van Der Heijde D, Braun J, Dougados M, Cush J, Clegg DO, et al. Recombinant human tumor necrosis factor receptor (etanercept) for treating ankylosing spondylitis: a randomized, controlled trial. Arthritis Rheum 2003;48:3230-6.
6. McGarry F, Neilly J, Anderson N, Sturrock R, Field M. A polymorphism within the interleukin 1 receptor antagonist (IL-1Ra) gene is associated with ankylosing spondylitis. Rheumatology (Oxford) 2001;40:1359-64.
7. Dinarello CA. The role of the interleukin-1-receptor antagonist in blocking inflammation mediated by interleukin-1. N Engl J Med 2000;343:732-4.
8. Nuki G, Bresnihan B, Bear MB, McCabe D. Long-term safety and maintenance of clinical improvement following treatment with anakinra (recombinant human interleukin-1 receptor antagonist) in patients with rheumatoid arthritis: extension phase of a randomized, double-blind, placebo-controlled trial. Arthritis Rheum 2002;46:2838-46.
9. Fleischmann RM, Schechtman J, Bennett R, Handel ML, Burmester GR, Tesser J, et al. Anakinra, a recombinant human interleukin-1 receptor antagonist (r-metHulL-1ra), in patients with rheumatoid arthritis: a large, international, multicenter, placebo-controlled trial. Arthritis Rheum 2003;48:927-34.
10. Garrett S, Jenlonson T, Kennedy LG, Whitelock H, Gasford P, Calin A. A new approach to defining disease status in ankylosing spondylitis: the Bath ankylosing spondylitis disease activity index. J Rheumatol 1994;21:2286-91.
11. Calin A, Garrett S, Whitelock HC, Kennedy LG, O'Hea J, Mallorie P, et al. A new approach to defining functional ability in ankylosing spondylitis. The Bath AS functional index. J Rheumatol 1994;21:2286-91.
12. Jenkinson TR, Mallorie PA, Whitelock HC, Kennedy LG, Garrett S, Calin A. Defining spinal mobility in ankylosing spondylitis. The Bath AS metrology index. J Rheumatol 1994;21:1694-8.
13. Anderson JJ, Baron G, van der Heijde D, Felson DT, Dougados M. Ankylosing spondylitis assessment group preliminary definition of short-term improvement in ankylosing spondylitis. Arthritis Rheum 2001;44:1876-86.
14. Braun J, Baraliakos X, Golder W, Brandt J, Rudwaleit M, Listing J, et al. Magnetic resonance imaging examinations of the spine in patients with ankylosing spondylitis, before and after successful therapy with infliximab: evaluation or a new scoring system. Arthritis Rheum 2003;48:1126-36.
15. Tan AL, Marzo-Ortega H, O'Connor P, Fraser A, Emery P, McGonagle DG. Efficacy of anakinra in active ankylosing spondylitis: a clinical and magnetic resonance imaging study. Ann Rheum Dis 2004, Apr 5 [Epub ahead of print].